FIRST PATIENTS HAVE BEEN ENROLLED IN A PHASE III STUDY IN ULCERATIVE COLITIS

OCT Clinical is running a Phase III study of the drug for the treatment of patients with ulcerative colitis. This is a multicenter, double-blind, randomized study, which is designed to assess the efficacy of the investigational product vs. active comparator. 

The recruitment target is 180 patients in Russia and Ukraine. First volunteers were enrolled in November 2019. All patients will complete the treatment by the end of 2020.

OCT Clinical is responsible for a wide range of activities, including regulatory support, logistics, patient enrollment, project management, clinical monitoring and site management.

Back to the list